Harrison, NYNCT06623396Now EnrollingIRB Ready

Mesothelin Positive Clinical Trial in Harrison, NY

Access cutting-edge mesothelin positive treatment through this clinical trial at a research site in Harrison. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Harrison location

Preparing your pre-screening questions…

Expert Care in Harrison

Access mesothelin positive specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mesothelin positive treatment provided free

Apply for This Harrison Location

Check if you qualify for this mesothelin positive clinical trial in Harrison, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Harrison

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Harrison site if eligible
  4. 4Begin participation

About This Mesothelin Positive Study in Harrison

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Aged ≥18 years
Diagnosis of pathologically confirmed EG adenocarcinoma
Diagnosis of metastatic or recurrent disease
ECOG performance status of 0-1
Life expectancy of ≥4 months Inclusion Criteria for Leukapheresis:
Written informed consent for the study (from participant)
Life expectancy of ≥4 months
ECOG performance status of 0-1
Histologic diagnosis that \& \>25% of the tumor expresses MSLN by IHC analysis. Archival tissue obtained up to 2 years before study enrollment is acceptable. IHC testing of a cell block from cytology (e.g., ascitic fluid) is acceptable if approved by the study pathologist. If adequate archival tissue is not available at screening, a fresh tumor biopsy should be obtained
Stage IV disease with gross peritoneal carcinomatosis on imaging and/or microscopic peritoneal involvement by cytology or noted during diagnostic laparoscopy
Disease progression or treatment intolerance after receiving at least 1 treatment regimen in the metastatic setting; patients with disease recurrence within 6 months of completing curative systemic therapy (chemotherapy, chemoradiation or adjuvant immunotherapy) are also eligible
Patients with Her2 positive disease must have received ≥1 line of anti-Her2 based therapy
At least 1 measurable or evaluable lesion per RECIST 1.1. Screening imaging must be obtained within 6 weeks of signing the informed consent form
Completion of systemic therapy at least 7 days before leukapheresis o Immune checkpoint inhibitor therapy must be completed at least 14 days before leukapheresis
Lab requirements (hematology):
Absolute neutrophil count ≥1.0 K/mcL
Hemoglobin ≥9 gm/dL
Platelet count ≥75 K/mcL
Blood product transfusion or growth factor support cannot occur within 7 days of testing
Lab requirements (serum chemistry):
Bilirubin ≤1.5× upper limit of normal (ULN)
Serum alanine aminotransferase and serum aspartate aminotransferase (ALT/AST) level ≤3× ULN
Calculated clearance of ≥50 mL/min by Cockcroft-Gault equation
Negative screen for infectious disease markers, including hepatitis B core antibody, hepatitis B surface antigen, hepatitis C antibody, HIV 1-2 antibody, HTLV antibody and syphilis antibody o Note: Patients with a history of hepatitis B virus infection are eligible if the hepatitis B viral load is undetectable. Patients with a history of hepatitis C virus infection who were treated for hepatitis C and cured are eligible if the hepatitis C viral load is undetectable
Serum pregnancy test with negative result at screening and preconditioning and must be willing to use effective and reliable contraception for at least 12 months after T cell infusion (for female participants of childbearing age)
Resolution of all acute toxic effects of any previous therapeutic or palliative chemotherapy, radiotherapy, or surgical procedures to grade ≤1 (CTCAE v5.0), except for neuropathy and alopecia Inclusion Criteria for lymphodepleting chemotherapy/CAR T cell infusion
Life expectancy of ≥4 months
ECOG performance status of 0-1
At least 1 measurable or evaluable lesion per RECIST 1.1. Screening imaging must be obtained within 4 weeks before the date of lymphodepletion
Completion of systemic therapy at least 14 days before lymphodepleting chemotherapy o Immune checkpoint inhibitor therapy must be completed at least 28 days before lymphodepleting chemotherapy
Lab requirements (hematology):
Absolute neutrophil count ≥1.5 K/mcL
Hemoglobin ≥8 gm/dL
Platelet count ≥75 K/mcL
Lab requirements (serum chemistry):
Bilirubin ≤1.5× upper limit of normal (ULN)
Serum alanine aminotransferase and serum aspartate aminotransferase (ALT/AST) level ≤3× ULN
Calculated clearance of ≥50 mL/min by Cockcroft-Gault equation
Serum pregnancy test with negative result within 7 days of planned lymphodepletion date and must be willing to use effective and reliable contraception for at least 12 months after T cell infusion (for female participants of childbearing age)
Resolution of all acute toxic effects of any previous therapeutic or palliative chemotherapy, radiotherapy, or surgical procedures to grade ≤1 (CTCAE v5.0), except for neuropathy and alopecia Participant

Exclusion Criteria

Pregnant or lactating
HIV, active hepatitis C virus, or active hepatitis B virus infection, as determined by quantitative PCR (patients who have undergone negative testing prior to leukapheresis do not require repeat testing)
Receiving therapy for concurrent active malignancy
Note: Patients receiving treatment for in situ skin malignancies are not excluded.
Patients with any malignancy diagnosed \>3 years before that is thought to be curatively treated and/or has a low risk of recurrence are eligible. Patients may continue to receive adjuvant therapy at the time of study enrollment (e.g., adjuvant hormonal therapy for curatively treated breast cancer).
Known hematologic malignancy requiring treatment in the preceding 5 years or a known history of lymphoid malignancy
Previous receipt of CAR T cell therapy or any other cellular therapy
Previous mesothelin-directed therapy Any major abdominal surgery (laparotomy with resection of gastrointestinal tract or organ resection) that is completed \<28 days before study enrollment. Patients who have undergone diagnostic laparoscopy can be included in the study without regard to timing
Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible if all of the following criteria are met:
Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study
Completion of radiotherapy ≥4 weeks before the screening radiographic study
Active autoimmune disease that has required systemic treatment within 1 year before leukapheresis (with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) o Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
Receiving daily systemic corticosteroids ≥10 mg of prednisone daily or equivalent or receiving immunosuppressive or immunomodulatory treatment
Any of the following cardiac conditions:
New York Heart Association stage III or IV congestive heart failure
Myocardial infarction ≤6 months before enrollment
History of myocarditis
Serious uncontrolled cardiac arrhythmia, unstable angina, or uncontrolled infection
Left ventricular ejection fraction ≤40%
Active interstitial lung disease/pneumonitis or a history of interstitial lung disease/pneumonitis requiring treatment with systemic steroids
Baseline pulse oximetry \<90% on room air at the screening time point
Known active infection requiring antibiotic treatment 7 days before leukapheresis o Note: Treatment can be delayed at the discretion of the treating physician to allow the patient to recover from the infection.
Any other medical condition, e.g. fever \>38.0 degrees C, that, in the opinion of the PI, may interfere with the subject's participation in or compliance with the study
Receipt of live, attenuated vaccine within 8 weeks before the planned lymphodepleting chemotherapy date
Deemed to be noncompliant by the study team for administration of a high-risk treatment agent and for close follow-up after treatment as required by the protocol

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Harrison?

Yes, this clinical trial (NCT06623396) has an active research site in Harrison, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mesothelin Positive Treatment Options in Harrison, NY

If you're searching for mesothelin positive treatment options in Harrison, NY, this clinical trial (NCT06623396) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Harrison research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mesothelin positive specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mesothelin positive clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Harrison, NY

See all myalgic encephalomyelitis clinical trials recruiting in Harrison — not just this study.

Browse Myalgic Encephalomyelitis Trials in Harrison →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Harrison?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Harrison, NY